Trump over and again creates buzz of false nationalist to grab the media coverage. It is trend now globally, politicians talk in all front without validated data. We strongly disagree with the observations made by USTR that India and China are involved in manufacturing substandard generic medicine. USTR is The Office of the United States Trade Representative is the United States government agency responsible for developing and recommending United States trade policy to the President of the United States.
There are two major reasons why USTR put allegation on Indian Pharmaceutical Industry, one Indian Pharma Industry exports 30% medicine to US alone followed by Africa 19% and European Union 16% and rest 35% to other parts of the world. Second point, we supply 50-100% more affordable generic medicine. Over 65% of India’s drug exports go to highly regulated market. No one can compete with china in raw material (API) production and in the same way no one can compete with India in finished product manufacturing.
India is the global hub of USFDA and UKMHRA approved manufacturing units. USTR should think about our investment in developing manufacturing plant, Investment in getting USFDA and UKMHRA approvals, investment in product development, investment in bioequivalence study, investment in clinical trial study, investment in reference standard, investment in toxicology, investment in regulatory compliance and investment in pharmacovigilance compliance. India exports 80% of anti HIV drugs to the world over. We are saving life of the humanity. Every year Nobel Prize in medicine should go to Indian Pharmaceutical Industry and no one else.
USTR should give letter of thanks to Indian Pharmaceutical Industry for valuable contribution in saving life of humanity and especially Americans because America imports 30% alone of Indian medicine. Indian has invested lot for safety of drugs and better administration of regulatory agency. Pharmacovigilance guideline implemented across India and national pharmacovigilance center is attached with international pharmacovigilance center. Now India is careful for every bit of adverse drug reaction anywhere in India, capturing them and sharing to the global community. CDSCO has expanded wings across India and world over for administration and control of safe medicine for global community.
Now, most of the country checks quality of medicine by involving third party inspection before dispatch of consignments. Recently chain of generic pharmacy such as Stay Happi and Dava India getting third party quality inspection before dispatch to the market place. They are selling medicine within India but caring every batch as they are exporting to US.
Mohammad Shahbaz Alam
For every challenge we face - unemployment, poverty, crime, income growth, income inequality, productivity, competitiveness - a great education is a major component of the solution. From Jawaharlal Nehru to Narendra Modi or any prime minister of India cannot fulfil commitment of employment because they do not know how. They do not know demand supply chain. Indian pharmaceutical industry is providing 10 million jobs for skilled and unskilled workers.
It is an old adage “Rome was not built in a day “Similarly global super power tag not attached to Indian Pharma Industries in a day. Regulators worked day and night in policy making, implementation and coordination with industry and global regulatory agencies for better administration. Two Singham, Dr.Surender Singh & Dr.G.N.Singh made CDSCO proactive and stronger in terms of transparency and administration.
Honourable regulators, legal advisors and manufacturers please justify as why stability is mandatory to get product permission whether old drug or a new drug. Sharing facts and asking questions as why it so happening into the pharmaceutical industry over and again. Drug and Cosmetic Act is in place to regulate the pharmaceutical industry then why everyday new circular is coming to the industry people.
E-pharmacies are recent entrants in the Indian e-commerce industry landscape, with it receiving increased attention from government and investors in the last three to five years. Today, the E-pharmacy market potential is worth over a 3,500 Crore with more than 35 startups assisting the growth of this segment in various regions of India. Inspite of being a novel segment in the Indian E - commerce industry, it is anticipated to grow at a CAGR of over 20%, crossing the 25,000 Cr mark by 2022.
Your email address will not be this published. Required fields are News Today.